Latest Interviews
Showing 1–3 of 3 transcripts.
Clear all filters- Milken Institute23 min
Conversation with CMS Administrator Mehmet Oz & HHS Chief Counselor Chris Klomp | Global Conference
Mehmet Oz, Chris Klomp, Esther Krofah
Under the strategic mandate "Making America Healthy Again," CMS Administrator Dr. Mehmet Oz and HHS leadership are overhauling the U.S. healthcare system by shifting from fee-for-service to value-based models that target upstream chronic disease prevention and address the nation's 27% unfilled prescription rate. The administration is enforcing strict integrity measures to eliminate $100 billion in annual fraud while simultaneously deploying AI to modernize legacy infrastructure and accelerate FDA drug approvals from 15 years to under five. These initiatives aim to align U.S. drug pricing with global "Most Favored Nation" standards and restore public trust in federal health agencies to counter competitive gaps with international rivals like China.
- Milken Institute22 min
A Conversation with FDA Commissioner Robert Califf | Future of Health Summit 2023
Robert Califf, Conrad Kiechel, Esther Krofah
FDA Commissioner Robert Califf highlighted a critical gap in U.S. health outcomes, noting that despite high spending, life expectancy has fallen to 76.4 years while fragmented post-market evidence systems fail to answer key treatment questions. To address this, Califf proposed a unified ecosystem involving the CMS, NIH, and FDA to leverage real-world data and AI for generating rigorous post-approval evidence while incentivizing clinicians to participate in large-scale research. Additionally, the agency plans to combat persistent public distrust and medical misinformation through plain-language communication and a broad coalition of academic, industry, and community partners.
- Milken Institute33 min
Global Health: Connectiveness for Better Outcomes | Asia Summit 2024
Esther Krofah, Mina Hamoodi, Ganen Sarvananthan, Tom Snow
Tom Snow's Snow Research Foundation, Lina Al Jaber's Mubadala, and Ganon Savaranthan's TPG Capital Asia outlined distinct strategies to accelerate healthcare innovation across the region through a combined focus on early-stage equity funding, sovereign wealth market expansion, and value-based service delivery. These leaders emphasized a shift from traditional grant models toward partnership-driven approaches that leverage local expertise to address Asia's unique demographic challenges, including rapid aging and the need for scalable clinical trials. By integrating advanced technologies like AI and electronic medical records with targeted investments in immunology, women's health, and infrastructure, the panelists aim to bridge the critical gap between academic discovery and commercial bedside application within one to two years.